On August 2, 2022, Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC) announced that it had completed its previously announced acquisition of Pharmadrug Production GmbH from Pharmadrug Inc. (CSE:PHRX) (OTC: LMLLF).
Khiron is a leading vertically integrated international medical
cannabis corporation with core operations in Latin America and
Europe. This acquisition will provide Khiron with a European
manufacturing and distribution hub for medical cannabis and other
pharmaceutical products, direct access to German pharmacies and
full control of its value chain, as well as a stronger market
presence with higher gross margins.
Gowling WLG advised Khiron with respect to this acquisition with a
team that included Peter Simeon, Jacob Cawker and Ashley Andaya
(corporate/M&A) and Paul Carenza (tax).
Read the original article on GowlingWLG.com.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.